Immunotherapies like the CART and PD-1 classes were what’s hot at ASCO this year. One wow moment: results of a proof-of-principal study indicating that CART therapies like the ones Novartis and Juno are working on can be effective against solid tumors as well as blood cancers.
Paging Dr. Watson! Wired/KHN checks in on the progress of AI diagnostics.
Following up on their hire of the inestimable ur-pharmablogger Ed Silverman, The Wall Street Journal has acquired the Pharmalot brand. Bookmark it, add it to your RSS reader, whatever it is the kids are doing these days to keep track of important things on the Interwebs.
Econoblogger/juice box mafioso Matthew Yglesias makes the case for nurses as cure-all for healthcare costs, doctor shortages, etc.